

System accuracy evaluation of the systems for selfmonitoring of blood glucose GL50 evo and GL 44 following DIN EN ISO 15197:2015 – A comparison of accuracy in hypo (<70 mg/dL)- and hyper glycemc (≥180 mg/dL) glucose ranges

Salzsieder E^{1*}, Puchert A¹, Ernst-Joachim Freyse¹ and Berg S^{1,2}

¹Institute of Diabetes, Gerhardt Katsch, Karlsburg, Germany

²University Medicine Greifswald, Germany

Abbreviations: CE: Conformance Europe; ISO: International Organization for Standardization; SMBG: Self-Monitoring of Blood Glucose.

Ongoing standardized verification of the accuracy of blood glucose meters systems for self-monitoring post-launch is important clinically and helps confirm appropriate continuous performance of self-monitoring blood glucose (SMBG) systems [1]. In addition, publication of such studies is increasingly becoming a component of evidence-based purchase decision making. ISO 15197:2015, [2] for which mandatory compliance is recommended for SMBG systems by 2015, [3] has tighter accuracy requirements than ISO 15197:2003, [4] and outlines current minimum accuracy standards necessary in Europe for CE marking.

In the present study, a postmarketing evaluation of the CE-marked GL50 evo and GL44 systems were performed in accordance with ISO 15197:2015 protocols and requirements. The GL50 evo and GL44 systems were supplied in Germany from the Beurer GmbH, Germany. A declaration of conformity from the manufacturer of the two measuring systems was available before the start of the study, so that only the GL50 evo was used in the tests, but the results documented the quality of both systems. Two GL50 evo systems (serial number: GL55 T1 and GL55 T2) and strips from 3 different lots (A 10/1, A 10/3, A 10/4) with expiry dates March 2017 respectively) were supplied by the manufacturer. The study was conducted from April 21 to May 05, 2015, at the Institute of Diabetes “Gerhardt Katsch,” Karlsburg, Germany. Ethical approval for the study was obtained from the Ethics Committee of the University of Greifswald in July 2014.

Ear lobe capillary blood samples were taken from 118 subjects for duplicate glucose determination using the GL50 evo and the glucose oxidase based YSI2300 STAT PLUS (YSI Incorporated, Yellow Springs, Ohio, USA) plasma glucose reference method. Trueness and precision of the comparison assay were verified using a range of YSI bioanalytical standards and controls. The prescribed limits for the hematocrit values, to be between 20% and 60%, were reached by the patient samples and after examination of glucose concentration ranges using the YSI, 52 subjects were evaluated in the study to consider the hypo- and hyperglycemic range.

To analyze the system accuracy of the monitoring system in hypo- (<70 mg/dL) and hyper-glycemic ranges (≥ 180 mg/dl) the statistic was done especially for these ranges.

In the glucose range <70 mg/dL in summary 100 % of the values and in the range ≥ 180 mg/dl in summary 98.2 % full filled the quality criteria of the ISO 15197. Important differences between the three tested lots were not shown; detailed data are presented in table 1. The table 2 and 3 demonstrates performance for the named hypo- and hyper-glycemic ranges, in relation to the minimum accuracy requirements of ISO 15197:2015 where for each of the 3 lots of strips at least 95% of results must fall within ±15 mg/dl of the comparison measurement results at blood glucose concentrations <100 mg/dl and within ±15% at

Table 1. System accuracy of Beurer GL50 evo/ GL44 for glucose concentrations <70 mg/dL

Strip lot	ISO 15197:2015 criteria		
	within ± 5mg/dL	within ± 10mg/dL	within ± 15mg/dL
A 10/1	13/30 (43.33 %)	29/30 (96.67 %)	30/30 (100 %)
A 10/3	15/30 (50.00 %)	30/30 (100 %)	30/30 (100 %)
A 10/4	23/30 (76.67 %)	30/30 (100 %)	30/30 (100 %)
Three lots in summary	51/90 (56.67 %)	89/90 (98.89 %)	90/90 (100 %)

Table 2. System accuracy of Beurer GL50 evo/ GL44 for glucose concentrations ≥180 mg/dL

Strip lot	ISO 15197:2015 criteria		
	within ± 5 %	within ± 10 %	within ± 15 %
A 10/1	29/74 (39.19 %)	56/74 (75.68 %)	73/74 (98.65 %)
A 10/3	29/74 (39.19 %)	58/74 (78.38 %)	72/74 (97.30 %)
A 10/4	30/74 (40.54 %)	63/74 (85.14 %)	73/74 (98.65 %)
Three lots in summary	88/222 (39.64 %)	177/222 (79.73 %)	218/222 (98.20 %)

*Correspondence to: Eckhard Salzsieder, Institute of Diabetes, Gerhardt Katsch, Karlsburg, Germany, E-mail: salzsied@diabetes-karlsburg.de

Received: September 02, 2019; Accepted: September 16, 2019; Published: September 18, 2019

Table 3. Numbers and percentages of results within system accuracy limits of ISO 15197:2015 at blood glucose levels <70 mg/dL and ≥180 mg/dL

SMBG system	ISO 15197:2015 criteria within ±15 mg/dl and ± 15%			
	Meter	Strip lot	Individual lots	3 lots combined
GL50 evo/	A 10/1	103/104 (99.04%)	308/312 (98.72%)	312/312 (100%)
GL44	A 10/3	102/104 (98.08%)		
	A 10/4	103/104 (99.04%)		

concentrations ≥100 mg/dl. The standard also requires that at least 99% of individual results fall within consensus error grid zones A and B [5,6] when clinical accuracy is evaluated with 3 test strip lots.

Conclusion

In conclusion, this study demonstrates that the GL50 evo and GL44 SMBG meter systems in hypo- and hyper-glycaemic ranges fulfils and exceeds the minimum analytical and clinical accuracy requirement of ISO 15197:2015. There are no differences in the accuracy between the glucose values <70 mg/dL and ≥180 mg/dL.

Acknowledgments

Beurer GmbH were permitted to review and comment on the manuscript, but final decision on content was retained by the authors.

Declaration of conflicts of interest

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: All authors are employees of the Institut of Diabetes, Karlsburg, Germany, which carries out studies evaluating blood glucose meter systems on behalf of various companies.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was funded by Beurer GmbH Söflinger Str 218, 89077 Ulm Germany.

References

1. Klonoff DC, Prahalad P (2015) Performance of cleared blood glucose monitors. *J Diabetes Sci Technol* 9: 895-910. [[Crossref](#)]
2. International Organization for Standardization. In vitro diagnostic test systems-requirements for blood-glucose monitoring systems for self-testing in managing diabetes mellitus. ISO 15197: 2013.
3. Baumstark A, Schmid C, Pleus S, Rittmeyer D, Haug C, et al. (2014) Accuracy assessment of an advanced blood glucose monitoring system for self-testing with three reagent system lots following ISO 15197:2013. *J Diabetes Sci Technol* 8: 1241-1242. [[Crossref](#)]
4. International Organization for Standardization. In vitro diagnostic test systems-requirements for blood-glucose monitoring systems for self-testing in managing diabetes mellitus. EN ISO 15197: 2003.
5. Parkes JL, Slatin SL, Pardo S, Ginsberg BH (2000) A new consensus error grid to evaluate the clinical significance of inaccuracies in the measurement of blood glucose. *Diabetes Care* 23: 1143-1148. [[Crossref](#)]
6. Bland JM, Altman DG (1986) Statistical methods for assessing agreement between two methods of clinical measurement. *Lancet* 1: 307-310. [[Crossref](#)]